Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CRHBP | P24387 | 1/20 | 0.40 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.40 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.37 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL657237 | 1.00 | MAPT (0.49) | MAPTSMN1; SMN2NPC1RAB9ANFKB1 | |
| SCHEMBL7895508 | 0.91 | MAPT (0.45) | MAPTSMN1; SMN2NPC1RAB9ANFKB1 | |
| SCHEMBL656896 | 0.86 | MAPT (0.50) | MAPTSMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL655185 | 0.82 | MAPT (0.49) | MAPTSMN1; SMN2NPC1RAB9ANFKB1 | |
| SCHEMBL655184 | 0.82 | MAPT (0.49) | MAPTSMN1; SMN2NPC1RAB9ANFKB1 | |
| SCHEMBL7892400 | 0.81 | MAPT (0.47) | MAPTSMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL656955 | 0.78 | MAPT (0.52) | MAPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL28017989 | 0.75 | ALDH1A1 (0.51) | MAPTSMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL7885636 | 0.74 | MAPT (0.47) | MAPTSMN1; SMN2MEN1KMT2AHSPB1 | |
| SCHEMBL3132216 | 0.73 | PTGS2 (0.56) | MAPTSMN1; SMN2LMNAPTGS2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993556-B2 | Resorcinol derivatives as HSP90 inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-03-31 | — | — | US | disclosed |
| US-8993556-B2 | Resorcinol derivatives as HSP90 inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-03-31 | — | — | US | disclosed |
| US-8993556-B2 | Resorcinol derivatives as HSP90 inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-03-31 | — | — | US | disclosed |
| EP-2421833-B1 | RESORCINOL DERIVATIVES AS HSP90 INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2015-01-14 | — | — | EP | disclosed |
| EP-2421833-B1 | RESORCINOL DERIVATIVES AS HSP90 INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2015-01-14 | — | — | EP | disclosed |
| EP-2421833-A1 | RESORCINOL DERIVATIVES AS HSP90 INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2012-02-29 | — | — | EP | disclosed |
| US-20120046266-A1 | RESORCINOL DERIVATIVES AS HSP90 INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-02-23 | — | — | US | disclosed |
| US-20120046266-A1 | RESORCINOL DERIVATIVES AS HSP90 INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-02-23 | — | — | US | disclosed |
| US-20120046266-A1 | RESORCINOL DERIVATIVES AS HSP90 INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-02-23 | — | — | US | disclosed |
| WO-2010121963-A1 | RESORCINOL DERIVATIVES AS HSP90 INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046266-A1 | RESORCINOL DERIVATIVES AS HSP90 INHIBITORS | HSP90AB1, HSP90AA1, HSP90AB2P | MAPT 84/4885SMN1; SMN2 2228/4885NPC1 824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.